Changes

Jump to: navigation, search

Boston Scientific - Company Profile

648 bytes removed, 10:01, 9 September 2011
/* Key Insights */
====Key Insights====
* Boston Scientific continues to focus on strategic initiatives to drive growth and profitability. Till now USA has been the major geographical market for this company but Japan is emerging post 2008* Recent acquisitions made by the company along with promising new technologies are expected to boost the company<nowiki>’</nowiki>'s pipeline. * However, the concern is with its core business where Boston is Scientifics' core businesses are witnessing significant pricing pressure and market decline. * Due to which the revenues have gone down by 4.70% for the fiscal year 2010.Moreover, the economic uncertainty is impacting its procedure volume.* For The dependence on Cardiovascular segment is very high and cannot be ignored. As its witnessing several challenges including pricing pressure, intense competition and slower market growth leading to a decline ranging between 3-8% annually * There are a few segments like urology/ women's health, neurovascular & Neuromodulation which have shown higher growth percentage that reaches up to 14% but the fiscal year 2010 the revenues contribution of the company has gone down by 4these segments is very low despite higher growth rate.70%Though this higher growth rate can be a signal of growth potential for future concentration of efforts * Company needs to realign their business portfolio to improve leverage and accelerate profitable revenue growth. The same decline Company's diversification in Neuromodulation has been contributed considered as a good decision by the various segments likeindustry professionals* Cardiovascular, Interventional Cardiology* Co. Faces certain industry risks such as failure of approval from FDA, approved devices being pulled from market due to safety reasons along with eroding market share and expiring patents. The recent example of pull back is the iCross Coronary stent systemImaging Catheters* Pacemakers* Electrophysiology and endoscopyIt's been noted that their long standing approach to growth is by strategic acquisitions of , investments in or alliances with other businesses or companies but the co. may not always be successful in generating growth this way * BSX needs to control costs, grow foreign market revenue and has to continue to get timely regulatory approvals. The decline Expansion of global sales and marketing focus is important along with Increasing its presence in these individual segments ranges from 3- 8 %* These businesses are witnessing several challenges including pricing pressuremarkets such as China, intense competition India and slower market growthBrazil and expanding the number of product registrations outside the U.S. 
* With respect to these declining figures new strategies need to be worked on, to either increase the contribution from this segment or diversify in to other segments
* The company has adopted <nowiki>’</nowiki>priority growth initiatives<nowiki>’</nowiki> based on which it will target non-DES and non-CRM areas that holds potential
* There are segments which have shown higher growth percentage that reaches up to 14% but the contribution of these segments is very low despite higher growth rate
* This higher growth rate can be a signal of growth potential for future concentration of efforts
* Segments like urology/ women<nowiki>’</nowiki>s health, neurovascular & Neuromodulation are growing post 2006 not significantly though
* Though company has diversified in neuromodulation which according to industry professionals has been considered a good decision
* Though the dependence on Cardiovascular is very high and cannot be ignored
* USA has been the major geographical market for this company but Japan is emerging post 2008
* Co also faces certain industry risks such as failure of approval from FDA, approved devices being pulled from market due to safety reasons along with eroding market share and expiring patents
* The recent example of pull back is iCross Coronary Imaging Catheters
* It<nowiki>’</nowiki>s being noted that their long standing approach to growth is by strategic acquisitions of , investments in or alliances with other businesses or companies
* But the co. may not always be successful in generating growth this way
* Co should try and leverage well on all the recent acquisitions so that the benefits can be reaped well
* Need to control costs, grow foreign market revenue and continue to get timely regulatory approval
* Company needs to realign their business portfolio to improve leverage and accelerate profitable revenue growth
* Expansion of global sales and marketing focus is important. Increasing the presence in markets such as China, India and Brazil by increasing their sales forces in emerging markets, expanding the number of our product registrations outside the U.S.
===Contact===